Diabetes pp 438-458 | Cite as

Weight Reduction in Diabetes

  • Stanley Schwartz
  • Anthony N. Fabricatore
  • Andrea Diamond
Part of the Advances in Experimental Medicine and Biology book series (AEMB)

Abstract

Obesity and diabetes incidence and prevalence are rampant in our Westernized civilization; they are both increasing andcarry with them many medical complications. There is clear evidence that aggressive treatment of these conditions, in particular preventing weight gain and ideally facilitating weight reduction in patients can minimize and reduce these complications. We review data supporting these observations, and review options and recommendations to support the practitioners in helping their patients achieve these goals safely.

Keywords

Triglyceride Glucagon Rosiglitazone Bromocriptine Glibenclamide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    World Health Organization. Obesity: preventing and Managing the Global Epidemic. WHO: Geneva 2000.Google Scholar
  2. 2.
    Finucane MM, Stevens GA, Cowan Mi et al. National, regional and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011; 377:557–567.PubMedCrossRefGoogle Scholar
  3. 3.
    Ogden CL. Carroll MD, Curtin LR et al. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 2006; 295:1549-1555.Google Scholar
  4. 4.
    Sturm R. Increases in clinically severe obesity in the United States, 1986–2000. Arch Intcn Med 2003; 163:2146–2148.CrossRefGoogle Scholar
  5. 5.
    Cowie CC, Rust KF. Byrd-Holt DD et al. Prevalence of diabetes and impaired fasting glucose in adults in the US population: National Health and Nutrition Examination Survey 1999–2002. Diabetes Care 2006; 29(6):1263–1268.PubMedCrossRefGoogle Scholar
  6. 6.
    Cowie CC, Rust KF, Ford ES et al. Full accounting of diabetes and prediabetes in the US population in 1988–1994 and 2005–2006. Diabetes Care 2009; 32(2):287–294.PubMedCrossRefGoogle Scholar
  7. 7.
    Ettaro L, Songer TJ, Zhang P et al. Cost-of-illness studies in diabetes mellitus. Phannacoeconomics 2004; 22(3): 149–164.CrossRefGoogle Scholar
  8. 8.
    Eeg-Olofsson K. Cederliolm J, Nilsson PM et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia 2009; 52(1):65–73.PubMedCrossRefGoogle Scholar
  9. 9.
    Haffner SM, Lehto S, Rönnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior rayocardial infarction. N Engl J Med 1998; 339(4):229–234.PubMedCrossRefGoogle Scholar
  10. 10.
    Khaw KT, Wareham N, Bingham S et al. Association of hemoglobin Alc with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141(6):413–420.PubMedCrossRefGoogle Scholar
  11. 11.
    Yamagishi S et al. Role of post prandial hyperglycemia in cardiovascular disease in diabetes, Int J din Pract 2007; 61:83–87.CrossRefGoogle Scholar
  12. 12.
    Tuomilehto J, Lindström J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343–1350.PubMedCrossRefGoogle Scholar
  13. 13.
    Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance (the Da Qing IGT and Diabetes Study). Diabetes Care 1997; 20:537–544.PubMedCrossRefGoogle Scholar
  14. 14.
    Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med 2002; 346:393–403.CrossRefGoogle Scholar
  15. 15.
    Chiasson JL, Josse RG, Gomis R et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359:2072–2077.PubMedCrossRefGoogle Scholar
  16. 16.
    Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic β-Cell function and frevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51(9):2796–2803.PubMedCrossRefGoogle Scholar
  17. 17.
    Torgerson JS, Hauptman J, Boldrin MN et al. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27(1): 155–161.PubMedCrossRefGoogle Scholar
  18. 18.
    Gerstein HC, Yusui S, Bosch J et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368:1096–1105.PubMedCrossRefGoogle Scholar
  19. 19.
    Delronzo RA, Tripathy D, Schwenke D et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Eng J Med 2011; 364(12):1104–1115.CrossRefGoogle Scholar
  20. 20.
    Stratton IM, Adler AI, Neil HA et al. Association of glycacmia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321(7258):405–412.PubMedCrossRefGoogle Scholar
  21. 21.
    UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131):837–853.CrossRefGoogle Scholar
  22. 22.
    Skyler JS, Bergenstal R, Bonow RO et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009; 32(1):187–192.PubMedCrossRefGoogle Scholar
  23. 23.
    Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979; 241(19):2035–2038.PubMedCrossRefGoogle Scholar
  24. 24.
    Wilson PW, Kannel WB, Silbershatz II et al. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999; 159(10):l 104–1109.CrossRefGoogle Scholar
  25. 25.
    Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003; 22(5):331–339.PubMedGoogle Scholar
  26. 26.
    Dagenais GR, Yi Q, Mann JF et al. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005; 149(l):54–60.PubMedCrossRefGoogle Scholar
  27. 27.
    Kim YI. Kim CH, Choi CS et al. Microalbuminuria is associated with the insulin resistance syndrome independent of hypertension and type 2 diabetes in the Korean population. Diabetes Res Clin Pract 2001; 52(2): 145–152.PubMedCrossRefGoogle Scholar
  28. 28.
    Franklin GM, Kahn LB, Baxter J et al. Sensory neuropathy in nou-insulin-depeudent diabetes mellitus: the San Luis Valley Diabetes Study. Am J Epidemiol 1990; 131(4):633–643.PubMedGoogle Scholar
  29. 29.
    Ziegler D, Rathmann W, Dickhaus T et al. Prevalence of polyneuropathy in prediabetes and diabetes is associated with abdominal obesity and macroangiopalhy: the MONICA/KORA Augsburg Surveys S2 and S 3. Diabetes Care 2008; 31(3):464–469.PubMedCrossRefGoogle Scholar
  30. 30.
    Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353(25):2643–2653.CrossRefGoogle Scholar
  31. 31.
    Holman RR, Paul SK, Bethel MA et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15):1577–1589.PubMedCrossRefGoogle Scholar
  32. 32.
    Duckworth W, Abraira C, Moritz T et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360(2): 129–139.PubMedCrossRefGoogle Scholar
  33. 33.
    Patel A, MacMahon S, Chalmers J et al. Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release and Controlled Evaluation (ADVANCE) Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358(24):2560–2572.PubMedCrossRefGoogle Scholar
  34. 34.
    Gerstein HC, Miller ME, Byington RP et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358(24):2545–2559.PubMedCrossRefGoogle Scholar
  35. 35.
    Reaven PD, Moritz TE, Schwenke DC et al. Veterans Affairs Diabetes Trial (VADT). Intensive glucose-loweringtherapy reduces cardiovascular disease events in Veterans Affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes 2009; 58(11):2642–2648.PubMedCrossRefGoogle Scholar
  36. 36.
    Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Circulation 2010; 122:844–846.PubMedCrossRefGoogle Scholar
  37. 37.
    Riddle MC, Ambrosius WT, Brillon DJ et al. Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3–4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010; 33(5):983–990.PubMedCrossRefGoogle Scholar
  38. 38.
    Boyko EJ. ACCORD glycemia results continue to puzzle. Diabetes Care 2010; 33(5): 1149–1150.PubMedCrossRefGoogle Scholar
  39. 39.
    Hypoglycemia associated with increased risk of MI among US veterans with diabetes [press release], Vienna, Austria: European Association for the Study of Diabetes (EASD) Annual Meeting; 2009. http://www.theheart.org/article/1010567.do. Accessed 2010.
  40. 40.
    Desouza C, Salazar H, Cheong B et al. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003; 26(5):1485–1489.PubMedCrossRefGoogle Scholar
  41. 41.
    Tanenberg RJ, Newton CA, Drake AJ. Confirmation of hypoglycemia in the “dead-in-bed” syndrome, as captured by a retrospective continuous glucose monitoring system. Endocr Pract 2010; 16(2):244–248.PubMedCrossRefGoogle Scholar
  42. 42.
    Tu E, Twigg SM, Semsarian C. Sudden death in type 1 diabetes: the mystery of the ‘dead in bed’ syndrome. Int J Cardiol 2010; 138(1):91–93.PubMedCrossRefGoogle Scholar
  43. 43.
    National Institutes of Health/National Heart Lung and Blood Institute, North American Association for the Study of Obesity. The Practical Guide: Identification, Evaluation and Treatment of Overweight and Obesity in Adults. National Institutes of Health: Bethesda, MD. 2000.Google Scholar
  44. 44.
    Dansinger ML, Gleason JA, Griffith JL et al. Comparison of the Atkins, Ornish, Weight Watchers and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005; 293:4–53.Google Scholar
  45. 45.
    Nordmann AJ. Nordmann A, Briel M et al. Effects of low-carbohydrate vs. low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med 2006; 166:285–293.PubMedCrossRefGoogle Scholar
  46. 46.
    Gardner CD, Kiazand A, Alhassan S et al. Comparison of the Atkins, Zone, Ornish and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A to Z Weight Loss Study: a randomized trial. JAMA 2007; 297:969–977.PubMedCrossRefGoogle Scholar
  47. 47.
    Pittas AG, Das SK, Hajduk CL et al. A low-glycemic load diet facilitates greater weight loss in overweight adults with high insulin secretion but not in overweight adults with low insulin secretion in the GALERIE trial. Diabetes Care 2005; 28:2939–2941.PubMedCrossRefGoogle Scholar
  48. 48.
    Ebbeling CB, Leidig MM, Feldman HA et al. Effects of a low-glycemic load vs. low-fat diet in obese young adults: a randomized trial. JAMA 2007; 297:2092–2102.PubMedCrossRefGoogle Scholar
  49. 49.
    Thomas DE, Elliott EJ, Baur L. Low glycaemic index or low glycaemic load diets for overweight and obesity. Cochrane Database Syst Rev 2007; CD 005105.Google Scholar
  50. 50.
    Thomas D, Elliott EJ. Low glycaemic index, or low glycaemic load, diets for diabetes mellitus. Cochrane Database Syst Rev 2009; CD 006296.Google Scholar
  51. 51.
    Fabricatore AN, Wadden TA, Ebbeling CB et al. Targeting dietary fat or glycemic load in the treatment of obesity and type 2 diabetes: a randomized controlled trial. Diabetes Res Clin Pract 2011; 92:37–45.PubMedCrossRefGoogle Scholar
  52. 52.
    [No authors listed]. Physical activity guidelines for Americans. Okla Nurse 2008–2009; 53(4): 25.Google Scholar
  53. 53.
    Andersen RE, Wadden TA, Bartlett SJ et al. Effects of lifestyle activity vs. structured aerobic exercise in obese women: a randomized trial. JAMA 1999; 281:335–340.PubMedCrossRefGoogle Scholar
  54. 54.
    Renjilian DA, Perri MG, Nezu AM et al. Individual versus group therapy for obesity: effects of matching participants to their treatment preferences. J Consult Clin Psychol 2001; 69:717–721.PubMedCrossRefGoogle Scholar
  55. 55.
    Fabricatore AN. Behavior therapy and cognitive-behavioral therapy of obesity: is there a difference? J Am Diet Assoc 2007; 107:92–99.PubMedCrossRefGoogle Scholar
  56. 56.
    Sarwer DB, von Sydow Green A, Vetter ML et al. Behavior therapy for obesity: where arc we now? Curr Opin Endocrinol Diabetes Obes 2009; 16:347–352.PubMedCrossRefGoogle Scholar
  57. 57.
    Ryan DH, Espeland MA, Foster GD et al. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003;24:610–628.PubMedCrossRefGoogle Scholar
  58. 58.
    Look AHEAD Research Group; Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 2007; 30(6): 1374–1383.CrossRefGoogle Scholar
  59. 59.
    Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170(17): 1566–1575.PubMedCrossRefGoogle Scholar
  60. 60.
    Ramachandran A, Snehalatha C, Mary S et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49:289–297.PubMedCrossRefGoogle Scholar
  61. 61.
    Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 2007; 30: 1374–1383.CrossRefGoogle Scholar
  62. 62.
    Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170: 1566–1575.CrossRefGoogle Scholar
  63. 63.
    Belalcazar LM, Reboussin DM, Haffner SM et al. A1-year lifestyle intervention for weight loss in individuals with type 2diabetes reduces high C-rcactivc protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care 2010; 33:2297–2303.PubMedCrossRefGoogle Scholar
  64. 64.
    Redmon JB, Bertoni AG, Connelly S et al. Effect of the Look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care 2010; 33:1153–1158.PubMedCrossRefGoogle Scholar
  65. 65.
    Lazo M, Solga SF, Horska A et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010; 33:2156–2163.PubMedCrossRefGoogle Scholar
  66. 66.
    Foy CG, Lewis CE, Hairston KG et al. Intensive lifestyle intervention improves physical function among obese adults with knee pain: findings from the Look AHEAD trial. Obesity 2011; 19:83–93.PubMedCrossRefGoogle Scholar
  67. 67.
    Foster GD, Borradaile KE, Sanders MH et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med 2009; 169:1619–1626.CrossRefGoogle Scholar
  68. 68.
    Lean ME, Powrie JK, Anderson AS et al. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990; 7(3):228–233.PubMedCrossRefGoogle Scholar
  69. 69.
    Williamson DF. Thompson TJ, Thun M et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23(10): 1499–1504.PubMedCrossRefGoogle Scholar
  70. 70.
    Whittemore R, Melkus G, Wagner J et al. Translating the diabetes prevention program to primary care: a pilot study. Nurs Res 2009; 58:2–12.PubMedCrossRefGoogle Scholar
  71. 71.
    Ackermann RT, Marrero DG. Adapting the Diabetes Prevention Program lifestyle intervention for delivery in the community: the YMCA model. Diabetes Educ 2007; 33:69, 74–75, 77-78.CrossRefGoogle Scholar
  72. 72.
    Digeuio AG, Mancuso JP, Gerber RA et al. Comparison of methods for delivering a lifestyle modification program for obese patients: a randomized trial. Ann Intern Med 2009; 150:255–262.CrossRefGoogle Scholar
  73. 73.
    Li Z, Maglione M, Tu W et al. Meta-analysis: pharmacologie treatment of obesity. Ann Intern Med 2005; 142(7):532–546.PubMedCrossRefGoogle Scholar
  74. 74.
    Rucker D, Padwal R, Li S et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194.PubMedCrossRefGoogle Scholar
  75. 75.
    Kaplan LM. Pharmacologic therapies for obesity. Gastroenterol Clin North Am 2010; 39(l):69–79.PubMedCrossRefGoogle Scholar
  76. 76.
    Mechanick JI. Kushner RF, Sugerman HJ et al. American Association of Clinical Endocrinologiste, The Obesity Society and American Society for Metabolic and Bariatric Surgery Medical Guidelines for Clinical Practice for the perioperative nutritional, metabolic and nonsurgical support of the bariatric surgery patient. Surg Obes Relat Dis 2008; 4(Suppl 5):S109–S 184.PubMedCrossRefGoogle Scholar
  77. 77.
    Scott WR, Batterham RL. Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: understanding weight-loss and improvements in type 2 diabetes after bariatric surgery. Am J Physiol Regul Integr Comp Physiol. 2011. [Epub ahead of print].Google Scholar
  78. 78.
    Vetter ML, Cardillo S, Rickeis MR et al. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med 2009; 150(2):94–103.PubMedCrossRefGoogle Scholar
  79. 79.
    Buchwald H, Estok R, Fahrbach K et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122(3):248–256.PubMedCrossRefGoogle Scholar
  80. 80.
    Groop L. Sulfonylureas in NIDDM. Diabetes Care 1992; 15:737–747.PubMedCrossRefGoogle Scholar
  81. 81.
    Nathan DM, Buse IB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32(1): 193–203.PubMedCrossRefGoogle Scholar
  82. 82.
    Klimt CR, Knatterud GL, Meinert CL et al. The University Group Diabetes Program: a study of the elfect of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. I. Design, methods and baseline characteristics. II. Mortality results. Diabetes 1970; 19(Suppl 2):747–830.Google Scholar
  83. 83.
    Tzoulaki I, Molokhia M, Curcin V et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drags: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731.PubMedCrossRefGoogle Scholar
  84. 84.
    Margolis DJ, Hoffstad OH, Strom BL. Association between serious ischemic cardiac outcomes and medications used to treat diabetes Pharmacoepidem Dr S 2008; (17):753–759.Google Scholar
  85. 85.
    UKPDS 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998; 352:837–853.PubMedGoogle Scholar
  86. 86.
    Malaisse WJ. Pharmacology of the meglitinide analogs: new treatment options fortype 2 diabetes mellitus. Treat Endocrinol 2003; 2:401–414.PubMedCrossRefGoogle Scholar
  87. 87.
    Rosenstock J, Hassman DR, Madder RD et al. Repaglinide versus Nateglinide monotherapy: arandomized, multicenter study. Diabetes Care 2004; 27:1265–1270.PubMedCrossRefGoogle Scholar
  88. 88.
    Gerich J, Raskin P, Jean-Louis L et al. PRESERVE-β: two-year efficacy and safety of initial combination therapy with Nateglinide or Glyburide plus Metformin. Diabetes Care 2005; 28:2093–2100.PubMedCrossRefGoogle Scholar
  89. 89.
    Kristensen JS, Frandsen KB, Bayer T et al. Compared with Repaglinide, sulfonylurea treatment in type 2 diabetes is associated with a 2.5 fold increase in symptomatic hypoglycemia with blood glucose levels 45 mg/dl (Abstract). Diabetes 49 (Suppl 1):A131, 2000.CrossRefGoogle Scholar
  90. 90.
    Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298(2): 194–206.PubMedCrossRefGoogle Scholar
  91. 91.
    Schwartz S. Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide. Curr Med Res Opin 2008; 24:3009–3022.PubMedCrossRefGoogle Scholar
  92. 92.
    Best JH, Hoogwerf BJ, Herman WH et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the Life Link database. Diabetes Care 2011; 34(l):90–95. Epub 2010.PubMedCrossRefGoogle Scholar
  93. 93.
    Chisholm JW, Goldfine AB, Dhalla AK et al. Effect of ranolazine on A1C and glucose levels inhyperglycemic patients with non ST elevation acute coronary syndrome. Diabetes Care 2010; 33(6): 1163–1168.PubMedCrossRefGoogle Scholar
  94. 94.
    Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574–583.PubMedCrossRefGoogle Scholar
  95. 95.
    DeFronzo R, Goodman A. Multicenter Metformin Study Group: Efficacy of Metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 541.PubMedCrossRefGoogle Scholar
  96. 96.
    Salpeter S, Greybcr E, Pasternak G et al. Risk of fatal and nonfatal lactic acidosis with Metfromin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006; CD 002967.Google Scholar
  97. 97.
    Diabetes Prevention Program Research Group. Reduction in incidence of type 2 diabetes with lifestyle intervention or Metformin. N Engl J Med 2002; 346:393–403.CrossRefGoogle Scholar
  98. 98.
    UK Prospective Diabetes Study (LIKPDS) Group. Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (LIKPDS 34). Lancet 1998; 352: 854–865.CrossRefGoogle Scholar
  99. 99.
    Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROACTIVE (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomized controlled trial. Lancet 2005; 366(9493): 1279–1289.PubMedCrossRefGoogle Scholar
  100. 100.
    Lincoff AM, Wolski K, Nicholls SJ et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298(10): 1180–1188.PubMedCrossRefGoogle Scholar
  101. 101.
    Lecka-Czernik B. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep 2010; 8(4): 178–184.PubMedCrossRefGoogle Scholar
  102. 102.
    Aithal GP, Thomas JA, Kaye PV et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008; 135(4): 1176–1184. Epub 2008.PubMedCrossRefGoogle Scholar
  103. 103.
    Gastaldelli A, Harrison S, Belfort-Aguiar R et al. Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment Pharmacol Ther 2010; 32(6):769–775.PubMedCrossRefGoogle Scholar
  104. 104.
    FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. US Food and Drug Administration. June 15, 2011. Available at http://www.fda.gov/Drugs/DrugSafety/ucm 259150.htm.
  105. 105.
    Kushner RF. Prevention of weight gain in adult patients with type 2 diabetes treated with pioglitazone. Obesity (Silver Spring) 2009; 17(5):1017–1022.CrossRefGoogle Scholar
  106. 106.
    Gupta AK, Smith SR, Greenway FL et al. Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome. Diabetes Obes Metab 2009; (4):330-7 11: 330–337.PubMedCrossRefGoogle Scholar
  107. 107.
    Lew P, Jellinger PS. The potential role of colesevelam in the management of prcdiabetes and type 2 diabetes. Postgrad Med 2010; 122(3)(Suppl 1): 1–8.Google Scholar
  108. 108.
    Holt RIG et al. Bromocriptine: old drug, new formulation and new indication. Diabetes, Obesity and Metabolism 2010; 12:1048–1057.PubMedCrossRefGoogle Scholar
  109. 109.
    Gaziano JM, Cincotta AH. O’Connor CM et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010; 33(7): 1503–1508.PubMedCrossRefGoogle Scholar
  110. 110.
    Scranton R, Cincotta A. Bromocriptine—unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother 2010; 11(2):269–279.PubMedCrossRefGoogle Scholar
  111. 111.
    Riddle M, Frias J, Zhang B et al. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care 2007; 30(11):2794–2799.PubMedCrossRefGoogle Scholar
  112. 112.
    Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15(6):540–559.PubMedCrossRefGoogle Scholar
  113. 113.
    Nathan DM, Roussell A, Godine JE. Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus: a randomized double-blind study. Ann Int Mod 1998; 334–340.Google Scholar
  114. 114.
    Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28:103–117.PubMedCrossRefGoogle Scholar
  115. 115.
    Abraira C, Johnson N, Colwell J et al. VA Co-operative study on glycemic control and complications in type II diabetes. Diabetes Care 1995; 18:1113–1123.PubMedCrossRefGoogle Scholar
  116. 116.
    Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes. Diabetes Care 2005; 28:2948–2961.PubMedCrossRefGoogle Scholar
  117. 117.
    Miller CD, Phillips LS, Ziemer DC et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Int Med 2005; 161:1653–1659.CrossRefGoogle Scholar
  118. 118.
    Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 1993; 329:978–986.Google Scholar
  119. 119.
    Miller CD, Phillips LS, Ziemer DC et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Int Med 2005; 161:1653–1659.CrossRefGoogle Scholar
  120. 120.
    Schwartz S, FACE, FACP et al. Glycemic control and weight reduction while avoiding hypoglycemia: the case for the continued safe aggressive care of patients with type 2 diabetes. Mayo Clin Proc 2010; 85(Suppl 12):S15–S 26.PubMedCrossRefGoogle Scholar
  121. 121.
    Nauck MA, Duran S, Kim D et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007; 50:259–267.PubMedCrossRefGoogle Scholar
  122. 122.
    Heine RJ, van Gaal LF, Johns D et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Int Med 2005; 143:559–569.PubMedCrossRefGoogle Scholar
  123. 123.
    Barnett AH, Burger J, Johns D et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: amultinational, randomized, open-label, two-period, crossover noniuferiority trial. Clin Ther 2007; 29:2333–2348.PubMedCrossRefGoogle Scholar
  124. 124.
    Davies M. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab 2009; 11(12): 1153–1162.PubMedCrossRefGoogle Scholar
  125. 125.
    Bunck MC. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles and oxidative stress. Atherosclerosis 2010; 212(l):223–229.PubMedCrossRefGoogle Scholar
  126. 126.
    DeFronzo RA, Okerson T, Viswanathan P et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagons secretion, gastric emptying and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008; 24(10):2943–2952.PubMedCrossRefGoogle Scholar
  127. 127.
    McFarland MS. Knight TN, Brown A et al. The continuation of oral medications with the initiation of insulin therapy in type 2 diabetes: a review of the evidence. South Med J 2010; 103:58–65.PubMedCrossRefGoogle Scholar
  128. 128.
    Rahbar S, Natarajan R, Yemeni K et al. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 2000; 301(1–2):65–77.PubMedCrossRefGoogle Scholar
  129. 129.
    Schwartz SS. Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled by diet, exercise and insulin administration. Diabetes, Metab Syndr Obes 2010;3:243–52.CrossRefGoogle Scholar
  130. 130.
    Thong KY, Jose B, Sukumar N et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Diabetes Obes Metab 2011; 1463–1326.Google Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2013

Authors and Affiliations

  • Stanley Schwartz
    • 1
    • 3
  • Anthony N. Fabricatore
    • 2
    • 4
  • Andrea Diamond
    • 5
  1. 1.Department of MedicinePhiladelphiaUSA
  2. 2.Department of PsychiatryUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  3. 3.Main Line Health SystemPhiladelphiaUSA
  4. 4.Department of Research and DevelopmentNutrisystem, Inc.Fort WashingtonUSA
  5. 5.Medical Nutrition, Nutrition Counseling SpecialistsBala CynwydUSA

Personalised recommendations